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catheters (ThermoCool RF and Arctic Front Advance cryoballoon) for
the treatment of drug refractory and symptomatic paroxysmal atrial
ﬁbrillation. Each tool is used to ablate the area surrounding the
pulmonary veins (PVs). However, no study has described and
quantiﬁed the ablated surface area after the application of cryoa-
blation lesions with the second-generation cryoballoon.
OBJECTIVE The purpose of this study was to determine the area of
ablation during cryoballoon PV isolation.
METHODS Preprocedural computed tomography angiography of
the left atrium (LA) was conducted in 43 patients to accurately
determine spatial chamber dimensions. Before and after the
ablation procedure, a detailed 3-dimensional electroanatomic
map of the LA was created and merged onto the computed
tomography angiogram to improve the accuracy of the data
recordings.
RESULTS The posterior LA wall had a mean surface area of 31.1
(1.6 SEM) cm2. Left- and right-sided antral PV surface areas of
cryoballoon ablation were not statistically different (P ¼ .935),
which were 11.4 (0.8 SEM) and 11.3 (0.8 SEM) cm2, respec-
tively. In total, 27% of the posterior LA wall remained unablated,Address reprint requests and correspondence: Dr David N. Kenigsberg,
Florida Heart Rhythm Specialist, 350 NW 84th Avenue, Suite 110,
Plantation, FL 33324. E-mail address: dkenigsb@yahoo.com.
1Ms Martin is an employee of St Jude Medical. Dr Lim is an employee of
Medtronic.
1547-5271 B 2015 Heart Rhythm Society. Open access under CC BY-NC-ND licenseelectrically functional, and homogeneous with regard to voltage
conductivity. This ablation strategy resulted in 95.3% freedom from
atrial ﬁbrillation at 6 months.
CONCLUSION The area of the posterior LA wall ablation with the
cryoballoon catheter is wide and antral, and the resulting posterior
LA wall debulking could be a part of the cryoballoon efﬁcacy beyond
discrete PV isolation.
KEYWORDS Atrial ﬁbrillation; Catheter ablation; Cryoballoon;
Cryoablation; Radiofrequency ablation; Wide area circumferential
ablation
ABBREVIATIONS 3D EAM ¼ 3-dimensional electroanatomic map;
AF ¼ atrial ﬁbrillation; ANOVA ¼ analysis of variance; CTA ¼
computed tomography angiography; eCRF ¼ electronic case report
form; LA ¼ left atrium/atrial; LIPV ¼ left inferior pulmonary vein;
LSPV ¼ left superior pulmonary vein; PNI ¼ phrenic nerve injury;
PV ¼ pulmonary vein; PVI ¼ pulmonary vein isolation; RIPV ¼
right inferior pulmonary vein; RSPV ¼ right superior pulmonary
vein; WACA ¼ wide area circumferential ablation
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Catheter ablation therapy has been given the highest level
recommendation (class I, level A) for the treatment of drug
refractory and symptomatic paroxysmal atrial ﬁbrillation
(AF) in the latest American College of Cardiology/American
Heart Association guidelines.1–3 A cornerstone of AF
ablation procedures is electrical isolation of the pulmonary
veins (PVs) by ablation lesions around the PVs.4Haïssaguerre et al4 originally described muscular sleeves
around the PV that are arrhythmogenic and are involved in
the initiation and maintenance of AF. Since the original
description, variations of this technique have included wide
area circumferential ablation (WACA) and pulmonary vein
antrum ablation/isolation. In addition, circular-architecture
ablation catheters have been designed with the intent of
performing pulmonary vein isolation (PVI) through the
simultaneous delivery of ablative energy, which are some-
times referred to as “single-shot” ablation catheters.
The cryoballoon catheter (Arctic Front Advance, Med-
tronic, Inc, Minneapolis, Minnesota) is an anatomically
based ablation device that allows for simpliﬁed PVI with a
favorable safety proﬁle.5 In practice, the cryoballoon catheterhttp://dx.doi.org/10.1016/j.hrthm.2014.11.012.
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ostium, resulting in cryothermal energy delivery to the
contacting atrial tissue and ultimately the formation of a
lesion.6 Given the spherical nature of the cryoballoon and
size mismatch of the balloon to the PV oriﬁce, quite often
the balloon is in physical contact with adjacent atrial tissue
away from the PV oriﬁce, creating a WACA as a common
lesion set.
With regard to ablation lesion(s) description and assess-
ment, 3-dimensional electroanatomic maps (3D EAMs) have
proved to be useful for measuring local voltage abnormalities
and they use this information as a surrogate for healthy vs
scarred (ablated) tissue.7–9 Also, previous correlations
between regions of cardiac scar (ablation) and low voltage
have been demonstrated.10–12 Scar burden has been used to
predict ablation efﬁcacy,13,14 stroke risk,15 and, more
recently, the site of PV reconnection in patients who have
undergone initial AF ablation, but had a recurrence of
arrhythmia.16 The extension of the scar (ablated cardiac
tissue) created by the cryoballoon during PVI had not been
previously studied with the second-generation cryoballoon.
Therefore, we attempted to calculate the area of acute
ablation produced after PVI using the cryoballoon catheter
that extends beyond the PV oriﬁce. In this study, we
compared the area of healthy tissue and ablation injury
before and after cryoablation.
Methods
This study examined 43 consecutive cryoballoon procedures
that encompassed a period of 6 months (October 15, 2013, to
April 11, 2014), and all patients were treated with the 28-mm
second-generation cryoballoon. The study design was a
single-arm, single-center, prospective collection of data
recorded in the electronic case report form (eCRF). All
patients were symptomatic and drug refractory with a history
of AF. Informed consent was obtained, and local institutional
review board approval was granted. The procedures per-
formed in this study were standard of care during the time
period of data collection.
Patient selection
Inclusion criteria for these 43 patients required a clinical
history of symptomatic AF, 1-drug refractory treatment of
AF, and AF ablation by PVI using a cryoballoon catheter.
Exclusion criteria were patients younger than 18 years,
patients older than 90 years, patients who have undergone
AF catheter ablation, patients undergoing extensive left atrial
(LA) substrate modiﬁcation instead of PVI (including com-
plex fractionated atrial electrogram ablation, focal impulse
and rotor modulation ablation, ablative isolation of the LA
appendage, or autonomic denervation via posterior LA wall
ablation), or patients with permanent AF.
3D EAM and cryoballoon ablation
All the cryoballoon ablation procedures were conducted by a
single experienced operator with more than 200 cryoablationprocedures at the time of this study. The procedural
techniques and methods for cryoballoon ablation have been
previously described in detail,5,17 and our own cryoablation
procedure was similar to those of published reports. In brief,
preprocedural cardiac computed tomography angiography
(CTA) was conducted in all 43 patients. On the day of
ablation, transesophageal echocardiography was routinely
conducted to assess the LA for thrombus, chamber size/
dimensions, and anatomical structures. Typically, an intra-
cardiac echocardiography catheter was used to visualize and
guide transseptal needle entry into the LA chamber.
Using CTA as guidance, a conventional 20-pole circular
diagnostic mapping catheter was advanced into each PV to
obtain baseline electrical information. The EnSite NavX
system (St Jude Medical, Inc) was used to create an electrical
impedance–based map of the entire LA surface. Speciﬁcally,
electroanatomic bipolar voltage-amplitude substrate map-
ping was completed with a minimum point setting at 100 mV
and a 2 mV demarcation for healthy tissue. After the
completion of electroanatomic mapping, the 3D EAM was
merged onto the CTA rendering.
Next, the cryoballoon catheter (28 mm, Arctic Front
Advance) and the sheath were delivered into the LA using a
J-tip guidewire or the Achieve inner lumen mapping catheter
(AchieveTM Mapping Catheter; Medtronic, Inc., Minneap-
olis, Minnesota). The balloon was advanced toward the PV
ostium and inﬂated. Cryoballoon-to-PV occlusion was tested
with the retention/leakage of contrast agent after injection at
the distal tip of the balloon. Subsequent to occlusion
veriﬁcation, a minimum of 2 freezes were delivered to each
PV with a targeted duration of 180 seconds. After the
completion of the ablation procedure, entrance and exit
block testing was used to conﬁrm PVI at each PV.
Then, postablation 3D electroanatomic mapping was
performed to assess voltage and ablation border demarcation,
as described previously.18,19 Brieﬂy, the proximal border of
PVI was denoted when there was a complete elimination of
electrograms, and this was assessed with the 3D EAM by
withdrawing the circular mapping catheter from the PV
toward the venoatrial junction. The PV ostium was assessed
by using the CTA-3D EAM merged image, and it was
located by the steep angle of change between the LA wall
and the tubular aspect of the PV. Precise spatial/electrical
measurements were mapped and recorded with the EnSite
NavX system (Figure 1). After each ablation procedure,
measurements of pre- and postablation dimensions were
recorded in the eCRF.Data recordings
Data that were recorded in the eCRF included LA volume
measurements, posterior LA wall surface area, and distances
to postablation lesions (at the superior and inferior margins
of each PV). As demonstrated in Figures 1–3, these measure-
ments (from the CTA-3D EAM merged image) were used to
calculate pre- and postablation surface areas in the LA. Each
distance measurement was recorded twice by 2 separate
Figure 1. Measurements of the left atrial (LA) dimensions recorded using the EnSite NavX system. The scale on the NavX voltage map was set from 0.2 to 1.2
mV. The purple region represents voltage4 1.2 mV, and the gray region represents voltageo 0.2 mV.A:Measurement system and mathematical formulas used
to calculate volumes and areas. The green transparent trapezoids demarcate the areas of right-sided ablation in this patient. Orange lines are recorded distances
measured with the NavX system. Yellow lines represent the measurements used to calculate the right superior pulmonary vein area of ablation. B and C:
Superior and inferior views of the same LA demonstrate the placement of measurements that were recorded. A/P ¼ anterior/posterior, R/S ¼ right/left; S/I ¼
superior/inferior.
Figure 2 Area of cryoballoon ablation in the left atrium (LA). A schematic depiction of the LA, with measurements and values reported. The blue-dotted zone
represents the cryoballoon ablated area. Numerical values are mean SD. LIPV¼ left inferior pulmonary vein; LSPV¼ left superior pulmonary vein; RIPV¼
right inferior pulmonary vein; RSPV ¼ right superior pulmonary vein.
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Figure 3 Pre- and postablation images recorded with the 3-dimensional electroanatomic mapping system. The scale on the NavX voltage map was set from
0.2 to 1.2 mV. The purple region represents voltage41.2 mV, and the gray region represents voltageo 0.2 mV. A: A preablation voltage map demonstrating
the posterior left atrial (LA) and 4 pulmonary veins. B: A postablation voltage map demonstrating cryoballoon lesion demarcation on the posterior LA wall.
Table 1 Demographic characteristics of the patients
Patient characteristic on the day of ablation Mean SEM SD
Age (y) 63.3 2.0 12.9
% Paroxysmal AF 79.1 6.3 41.2
% Male 74.4 6.7 44.2
Left atrial volume (mL) 70.8 5.5 36.0
No. of PVs per patient 4.1 0.1 0.5
LSPV diameter (cm) 2.0 0.1 0.3
LIPV diameter (cm) 1.8 0.1 0.3
RSPV diameter (cm) 2.0 0.1 0.3
RIPV diameter (cm) 1.9 0.1 0.3
% presenting in NSR 72.1 6.9 45.4
% receiving AADs 86.1 5.4 35.1
No. of AADs 1.0 0.1 0.6
% receiving anticoagulant 90.7 4.5 29.4
% receiving aspirin 23.3 6.5 42.8
% receiving NOAC* 51.2 7.7 50.6
% receiving other† 7.0 3.9 25.8
% receiving warfarin 14.0 5.4 35.1
AAD ¼ antiarrhythmic drug; AF ¼ atrial ﬁbrillation; LIPV ¼ left inferior
pulmonary vein; LSPV ¼ left superior pulmonary vein; NOAC ¼ novel oral
anticoagulant; NSR¼ normal sinus rhythm; RIPV¼ right inferior pulmonary
vein; RSPV ¼ right superior pulmonary vein.
*NOAC ¼ apixaban, dabigatran, or rivaroxaban.
†Other ¼ enoxaparin or clopidogrel.
Heart Rhythm, Vol 12, No 2, February 2015286investigators, and the 2 data records showed 90% reprodu-
cibility. When measurements were different, the mean
distance (between the 2 investigators) was recorded. Ana-
tomical cardiac measurements (Figure 1A) were made in
accordance to previously published studies.18,19 In brief, LA
volume was calculated from anterior/posterior, right/left, and
superior/inferior recorded data by using an ellipsoid model.
The posterior wall surface area was calculated from right/left
and superior/inferior measurements of the LA, and surface
areas of left- and right-sided LA ablation procedures were
calculated from distances to postablation lesion measure-
ments by using a trapezoidal rule model.
Statistical analyses
All descriptive statistics are recorded as means with reported
SEM and SD. Means are reported with the number of
individual observations used to calculate each statistical
parameter. For 2-sample comparisons of continuous varia-
bles, a Student t test was used to determine statistically
signiﬁcant interactions. When multiple samples were com-
pared, an analysis of variance (ANOVA) test was used to
examine whether populations were statistically different, and
the outlier group(s) were identiﬁed within each table.
Statistical signiﬁcance was set at Po .05, and all statistical
analyses were calculated using Minitab (Minitab, Inc.)
Results
Demographic data of the 43 consecutive patients enrolled in
the study are given in Table 1. Table 2 lists the characteristics
of cryoablation procedures used in this study. The mean
number of cryoballoon freezes ranged from 2.0 (0 SD) to
2.5 (1.3 SD) applications per vein (median 2.0; mode 2.0).
The mean number of right inferior pulmonary vein (RIPV)
applications were found to be signiﬁcantly higher using the
ANOVA test (P ¼ .012). The mean freeze duration per
application was 169 (29 SD), 178 (10 SD), 159 (38
SD), and 169 (31 SD) seconds for the left superior
pulmonary vein (LSPV), left inferior pulmonary vein(LIPV), right superior pulmonary vein (RSPV), and RIPV,
respectively (median 180 seconds; mode 180 seconds). The
mean freeze duration for the LIPV was found to be statisti-
cally longer and for the RSPV statistically shorter than that
for the other PVs using the ANOVA test (P¼ .001). Typical
(target) freeze times were 180 seconds, with shorter dura-
tions representing freeze terminations based on electrical
isolation of the PVs, ultracold balloon nadir temperature
(o 60oC), or an attempt to avoid collateral tissue freezing
(eg, phrenic nerve). The mean freeze nadir temperatures
were 47 (7 SD), –45 (7 SD), 48 (7 SD), and 45
(6 SD)1C for the LSPV, LIPV, RSPV, and RIPV,
respectively (median 471C; mode 481C). The nadir
temperatures recorded at the superior veins were found to
be higher than those recorded at the inferior veins using the
Table 2 Procedural characteristics
Cryoballoon freeze characteristic Mean SEM SD P
No. of freeze applications
LSPV 2.3 0.1 0.7
LIPV 2.0 0 0 .012*
RSPV 2.1 0.1 0.5
RIPV 2.5† 0.2 1.3
Freeze duration (s)
LSPV (n ¼ 101) 169.3 2.8 28.5
LIPV (n ¼ 68) 178.1† 1.2 10.0 .001*
RSPV (n ¼ 92) 158.5† 4.0 38.2
RIPV (n ¼ 109) 168.5 3.0 31.2
Nadir temperature (1C)
LSPV (n ¼ 101) 47.2† 0.7 7.1
LIPV (n ¼ 68) 44.8 0.8 6.8 .001*
RSPV (n ¼ 92) 48.3† 0.7 7.1
RIPV (n ¼ 109) 45.0 0.6 6.4
Procedure time (min) 126.4 3.5 22.7
LA dwell time (min) 80.6 2.6 16.7
Fluoroscopy time (min) 16.4 1.2 7.5
IV saline ﬂuid use (mL) 1418.8 79.9 505.4
Radiopaque contrast (mL) 45.5 4.2 25.3
IV ¼ intravenous; LA ¼ left atrial; LIPV ¼ left inferior pulmonary vein;
LSPV ¼ left superior pulmonary vein; RIPV ¼ right inferior pulmonary vein;
RSPV ¼ right superior pulmonary vein.
*Signiﬁcant P value.
†The outlier group(s).
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time, and ﬂuoroscopy time were recorded as 126 (23 SD;
median 121; mode 120), 80 (17 SD; median 80; mode 60),
and 16 (8 SD; median 15; mode 19) minutes, respectively.
LA measurements of pre- and postablation cardiac
dimensions are reported in Table 3. Left- and right-sided
LA ablation procedures were not statistically different
(P ¼ .935), and each had a mean posterior LA wall surface
area of ablation of 11.4 (5.3 SD; median 10; mode 9) and
11.3 (5.2 SD; median 10; mode 8) cm2, respectively
(Figure 3). On average, the total posterior LA wall surface
area was 31.1 (10.2 SD; median 30; mode 37) cm2, and
the mean surface area of the nonablated posterior wall was
8.4 (8.2 SD; median 6; mode 6) cm2, which was typically
a vertical rectangular-shaped zone in most patients
(Figures 1A and 3B). In total, 27% (21.9% SD) of the
posterior LA wall remained electrically intact and unab-
lated. The total area of posterior wall ablation was 22.7Table 3 LA measurements of pre- and postablation cardiac
dimensions
LA dimension measurement Mean SEM SD
Preablation: posterior LA wall surface area (cm2) 31.1 1.6 10.2
Postablation: posterior LA wall surface area (cm2)
Left-sided 11.4 0.8 5.3
Right-sided 11.3 0.8 5.2
Postablation: posterior LA wall not ablated
Central zone surface area (cm2) 8.4 1.3 8.2
Postablation: distance from the PV to the
ablation edge (cm)
1.9 0.1 0.7
LA ¼ left atrium; PV ¼ pulmonary vein.(10.1 SD) cm2; by comparison, each cryoballoon has a 2-
dimensional contact area of 6.15 cm2 when measuring
from the tip to the equator of the cryoballoon (in the 28-mm
cryoballoon). The distribution zone of the liquid nitrous
oxide within the second-generation cryoballoon encom-
passes a surface area from the distal nose tip to the equator
of the balloon. Consequently, the hypothetical contact
surface area of 4 PVs calculated in the 28-mm cryoballoon
is 24.6 cm2, which is in close approximation of the 22.7
cm2 mean ablation area that was reported in this study
(Figure 4).
As shown in Table 3, the measured distance from the
proximal PV to the cryoballoon PVI ablation edge had a
mean value of 1.9 (0.7 SD; median 1.8; mode 1.8) cm,
which had a 1-to-1 relationship with the approximately 2-cm
distance (from the nose tip to the equator of the cryoballoon)
that was available for ablation in the 28-mm Arctic Front
Advance cryoballoon. When measured at each PV, the
distance from the PV to the ablation edge had a mean value
of 1.7 (0.7 SD; median 1.7; mode 1.9), 1.7 (0.6 SD;
median 1.6; mode 1.5), 1.8 (0.7 SD; median 1.6; mode 1.6),
and 2.3 (0.7 SD; median 2.3; mode 1.8) cm for the LPSV,
LIPV, RSPV, and RIPV, respectively. Using the ANOVA
test, we found that the RIPV had a statistically longer distance
from the PV to the PVI ablation edge (P ¼ .001).
After the completion of this study, all 43 patients had
undergone electrophysiology examination at 1, 3, and 6
months postablation with ambulatory cardiac monitoring.
Two patients had a recurrence of AF, and 41 patients (out ofFigure 4 Bar graph of the mean posterior left atrial (LA) wall surface
areas in 43 patients (gray bar). After cryoballoon ablation, the posterior LA
wall had a central zone that was unablated (red bar). This nonablated zone
(red bar) was 27% of the posterior LA wall on average, and there was no
statistical difference between areas of left- and right-sided ablation proce-
dures (blue bars; P ¼ .935). The black bar represents the surface area of the
refrigerant spray (from the distal nose tip to the equator of the cryoballoon)
in the 28-mm cryoballoon. Error bars represent 1 SEM. LF ¼ left; PV ¼
pulmonary vein; RT ¼ right.
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procedure (95.3% freedom from AF). The mean follow-up
period was 9.2 (2.1 SD; range 6–13) months for the entire
patient cohort.Discussion
To date, this study is the ﬁrst quantitative examination of the
ablative lesion set created by the second-generation cryobal-
loon, and in this study, we exclusively used the 28-mm Arctic
Front Advance cryoballoon catheter in 43 consecutive
patients. By using only the 28-mm second-generation cry-
oballoon in 43 consecutive patients, we have established the
quantitative spatial measurements of the WACA lesion sets
created by cryoablation under current and typical usage
patterns, which were in agreement with a recent multicenter
examination of cryoballoon procedural measurements.20 The
antral lesion placement creates an ablation set that leaves 27%
of the posterior LA wall intact. This LA debulking by the
cryoballoon catheter may have a beneﬁcial outcome with
regard to longer-term efﬁcacy.Whenmeasuring distance from
the PV to the ablation edge, the RIPV had a statistically longer
mean distance (2.3 cm) in this study than did the other 3 PVs.
Interestingly, the RIPV also had a statistically higher mean
number of freeze applications than did the other 3 PVs. By
comparison, the LIPV had the longest mean freeze duration
and the RSPV had the lowest mean nadir temperature.
Two small studies18,19 have been previously published for
the ﬁrst-generation cryoballoon system. In the study by
Chierchia et al,18 the researchers examined 8 patients (4
treated with the 23-mm cryoballoon and 4 treated with the
28-mm cryoballoon). Although limited surface area calcu-
lations were reported, this study found an approximately 2-
cm linear zone of ablation that surrounds each PV while
using 3D EAM measurements, which was similar to the 1.9-
cm distance recorded in the present study. In addition, the
lesion created with the 28-mm cryoballoon was more antral
in position when compared statistically with the 23-mm
cryoballoon lesion. On average, the lesions in the study by
Chierchia et al were created with 5-minute cryoablation
applications and 2 ablation procedures per PV, with a target
nadir temperature of lower than 40oC. These longer
application times were typical usage patterns during the
usage of the ﬁrst-generation cryoballoon because of limited
cryo-refrigerant distribution in the ﬁrst-generation balloon.
By comparison, an earlier study by Reddy et al19 eval-
uated 8 patients treated only with the 23-mm ﬁrst-generation
cryoballoon. By using a 3D EAM protocol similar to that
used in our study and the study by Chierchia et al, Reddy
et al found that the lesion sets resided near the PV ostium
with little antral penetration by the cryoablation lesion set.
Since the original publication of the results of Reddy et al,
there has been a predominant usage of the 28-mm cryobal-
loon because of the ability to create an antral lesion set and
the perceived potential to reduce the incidence rate of PV
stenosis. More recently, physicians have adopted a typical
usage strategy that reserves the usage of the 23-mmcryoballoon to patients in whom all PVs have a measured
diameter of less than approximately 16 mm. In cases where
there are mismatched vein sizes, the 28-mm cryoballoon is
used singularly when any PV has a diameter of 18 mm or
greater because of the larger freezing surface area in the
second-generation cryoballoon, which covers small and
large PVs. Interestingly, by current “typical” physician
usage, all 8 patients in the study by Reddy et al would have
been ablated with the 28-mm cryoballoon. At present, more
than 80% of all cryoballoon usage is with the 28-mm balloon
(Medtronic data).
Since the original surgical Cox Maze procedure, intra-
cardiac ablation strategies have been worked out to recreate a
safe and durable lesion set for the treatment of AF. The
Haïssaguerre PVI strategy has been successful in many
patients with AF. More recently, some speciﬁc strategies
of substrate ablation have proved to be interesting, including
ganglionic plexus21,22 and rotor ablation procedures.23,24
While we await more trial data, it is interesting that this
second-generation cryoballoon creates lesions that are near
the ganglionic plexi on the LA posterior wall.21 Additionally
many stable rotors have been found near the “PV ostia-to-LA
antrium” border which is contiguous with the area of
cryoballoon ablation.24 Consequently, recent improved
1-year outcomes with the second-generation cryoballoon
may reﬂect this lesion set that is wide and circumferential, as
denoted by the present study. With the second-generation
cryoballoon system, 5 independent published studies have
demonstrated a 12-month efﬁcacy of 80% or more.17,25–28
Two of these studies had a comparator arm with the ﬁrst-
generation cryoballoon and demonstrated an 18%–20%
improvement in efﬁcacy.17,25
However, with a wider lesion set, more care is necessary
to avoid collateral tissue damage near the posterior LA wall,
including the phrenic nerve. Compared to radiofrequency
catheter ablation, the cryoballoon lesion enhances the risk of
phrenic nerve injury (PNI), both transient and longer-term.2,5
More recent phrenic nerve monitoring techniques have
lowered the risk of PNI,29 but the increased occurrence of
PNI during a cryoballoon ablation compared to RF ablation
for PVI is both a consequence of and evidence for the wide
and transmural cryoballoon lesion set.
Study limitations
To minimize user variation in cryoballoon handling during
this study, all cryoballoon ablation procedures were con-
ducted by 1 experienced physician. This study design
allowed for a robust measure in multiple patients and
reported mean values; however, the design did not allow
for the culmination of multiple user experience with the
cryoballoon. In addition, we do not know the surface area
measurements of the cryoballoon lesion set at 6–12 months.
Conclusion
This study has demonstrated the WACA lesion formation
that is observable acutely by using 3D electroanatomic
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areas of ablation were similar. Acutely after ablation, 27% of
the posterior LA wall remained intact and electrically
conductive. At 6 months postablation, 95.3% of all patients
remained free of AF with a single cryoablation procedure.
Even with a geometrically derived ablation volume, the
cryoballoon catheter was able to form a WACA lesion set.
The earlier usage of the ﬁrst-generation cryoballoon was
constrained by the limited balloon surface coverage of the
cryo-refrigerant and by selective usage of the 23-mm
cryoballoon, which led to a lesion set near the PV ostium.
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This study is the ﬁrst demonstration of the acute ablation zone that is established after cryoablation with the new Arctic
Front Advance cryoballoon catheter. Because of an increased area of refrigerant distribution in the new balloon, users will
ﬁnd that the established pulmonary vein isolation lesion set is a wide area circumferential ablation. The remaining (intact)
posterior left atrial wall is electrically conductive and approximately 27% of the original surface area, and the border
demarcation between ablated and nonablated cardiac tissue demonstrates a sharp voltage gradient, which may be indicative
of acute transmural lesion formation.
This larger area of antral ablation may explain (in part) the improved 12-month efﬁcacy that is observed with the new
cryoballoon, as 5 independent studies have reported more than 80% freedom from AF. It is well established that there is a
prevalence of electrical disruption (eg, rotors and ganglionic plexi) on the posterior left atrial wall that can severe as
triggers/propagators/sustainers for AF. However, the new cryoballoon must be used with a reﬁnement in procedural
application (mainly reduced freeze dosing/duration). Phrenic nerve injury is still possible with the second-generation
cryoballoon, and novel monitoring techniques may provide better surveillance of impending damage. In this study,
cryoballoon freeze applications were typically less than 3 minutes, and by comparison, older reports on ﬁrst-generation
cryoballoon have used 5-minute applications. More than 90% freedom from AF, at 6 months in this study, indicates that
these shorter freeze applications are still effective.
